Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Topical tazarotene effective in congenital ichthyosis

Feb. 18, 2000

No Comments

Antipsoriatic activity of EGF receptor tyrosine kinase inhibitor SU-5271

Feb. 15, 2000

No Comments

Clearance to begin clinical trial of novel acne treatment sought by Praxis

Feb. 14, 2000

No Comments

Hair growth promoter described by BMS for use in male pattern baldness

Feb. 9, 2000

No Comments

Methods of wound healing using amphipathic peptides from Demegen

Feb. 8, 2000

No Comments

New Sumitomo compounds inhibit cytokine and IgE production

Feb. 8, 2000

No Comments

Cellegy to commence phase II trial of Anogesic as hemorrhoid treatment

Feb. 8, 2000

No Comments

Alexion to commence development of 5G1.1 for treatment of dermatomyositis

Feb. 3, 2000

No Comments

IGI and Fujisawa collaborate on topical formulations of dermatological product

Jan. 27, 2000

No Comments

Micrologix Biotech commences phase I trial for acne therapy

Jan. 25, 2000

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

BioWorld Science, Dermatologic
RSS

Topical tazarotene effective in congenital ichthyosis

Antipsoriatic activity of EGF receptor tyrosine kinase inhibitor SU-5271

Clearance to begin clinical trial of novel acne treatment sought by Praxis

Hair growth promoter described by BMS for use in male pattern baldness

Methods of wound healing using amphipathic peptides from Demegen

New Sumitomo compounds inhibit cytokine and IgE production

Cellegy to commence phase II trial of Anogesic as hemorrhoid treatment

Alexion to commence development of 5G1.1 for treatment of dermatomyositis

IGI and Fujisawa collaborate on topical formulations of dermatological product

Micrologix Biotech commences phase I trial for acne therapy

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

BioWorld Science, Dermatologic RSS

BioWorld Science, Dermatologic
RSS